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Abstract
Introduction: Insulin allergy may occur in patients treated with subcutaneous applications of
insulin preparations. Besides additives in the insulin preparation such as protamine, cresol, and
phenol, the insulin molecule itself may be the cause of the allergy. In the latter case, therapeutic
options are rare.
Case presentation: A 68-year-old man with poorly controlled type 2 diabetes mellitus received
different insulin preparations subcutaneously while on oral medication. Six to eight hours after each
subcutaneous application, he developed pruritic plaques with a diameter of >15 cm at the injection
sites that persisted for several days. Allergologic testing revealed positive reactions against every
insulin preparation and against protamine. Investigation of serum samples demonstrated IgG
antibodies against human and porcine insulin. We treated the patient with human insulin using an
ultra-rush protocol beginning with 0.004 IU and a rapid augmentation in dose up to 5 IU. Therapy
was accompanied by antihistamine therapy. Subsequent conversion to therapy with glargine insulin
(6 IE twice daily) was well-tolerated.
Conclusion: As reported in this case, desensitization with subcutaneously administered human
insulin using an ultra-rush protocol in patients with an insulin allergy may present an easy form of
therapy that is successful within a few days.
Introduction
In the past, when unpurified insulins were used, allergic
reactions to the drug were reported in 10% to 56% of
patients [1]. Since human insulin and its analogues have
been introduced, insulin allergies are rare and currently
reported in only 0.1% to 2% of all patients treated with
insulin [2]. In most cases, allergic reactions are restricted
to the skin and are either of a local immediate or delayed
reaction type. These skin reactions are often self-limited
under continuation of therapy. However, systemic, poten-
tially life-threatening reactions such as urticaria or anaph-
ylaxis have also been reported [1]. Both types of
hypersensitivity may result from the insulin molecule
itself, and also from protamine, which is used in many
preparations to delay insulin absorption [3-5]. Protamine
sulphate is a low-molecular weight polycationic protein
isolated from sperm of salmon or salmon-like fish.
Besides its use as an insulin additive, protamine is also
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used to reverse the therapeutic effects of heparin. The
intravenous or subcutaneous administration of pro-
tamine can provoke pseudoallergic reactions through
non-immune mediated histamine release [5]. In patients
with diabetes mellitus, subcutaneous administration of
protamine-containing insulin preparations can also pro-
voke delayed, T-cell mediated skin reactions or granulo-
matous hypersensitivity [6]. In addition to protamine,
cresol and phenol, which both serve as preservatives in
pharmaceutical products, may provoke allergic reactions
[7].
Successful treatment of insulin allergies has been reported
using a continuous subcutaneous pump infusion of insu-
lin [8-10], switching from human insulin to insulin aspart
or lispro [11,12], or in severe cases, by pancreas transplan-
tation [13,14].
In the case presented, we suggest tolerance induction
using an ultra-rush desensitization protocol as an easy-to-
perform and well-tolerated therapy for patients with insu-
lin allergies.
Case presentation
We evaluated a 68-year-old man in our dermatologic out-
patient unit. He suffered from type 2 diabetes and was ini-
tially treated with oral anti-diabetic medication. As
normoglycaemia was not being achieved using maximal
oral treatment and a low caloric diet, the patient was
treated with insulin. The administration of different insu-
lins (i.e. insulin detemir, insulin glargine, and human
insulin) resulted in the development of pruritic plaques
with a diameter of >15 cm at each injection site and which
persisted for several days. Splitting of the dose and chang-
ing of the injection sites were not successful in resolving
the reaction. Local factors, such as poor injection tech-
nique, misuse of the insulin injector, incorrect use of local
disinfectants, or contact allergy to disinfectants were ruled
out.
Skin tests
Intradermal tests were performed with 0.05 ml of differ-
ent standard insulins and with a Lantus© test kit from
Sanofi Aventis (Frankfurt/Main, Germany) on the volar
forearm. Physiological saline and histamine (0.01% hista-
mine solution; Bencard, Munich, Germany) served as con-
trols. Table 1 shows the results of intradermal testing in
detail. Figures 1 and 2 show positive intradermal testing
with  Levemir©, Huminsulin basal© Humalog©, and Lantus©
(Fig. 1) and positive reactions against protamine-contain-
ing test solutions (Fig. 2).
Table 1: Substances used in intradermal testing
Substance 20 minutes 24 hours 48 hours
1 Levemir© (insulin glargine, m-cresol, glycerol) + ++ ++
2 Huminsulin basal© (human insulin, m-cresol, phenol, glycerol, protamine) + ++ ++
3 Lantus© (insulin glargine, m-cresol, glycerol) + ++ ++
4 Actrapid penfill© (human insulin, m-cresol, glycerol) + ++ ++
5 Insuman rapid© (human insulin, m-cresol) + ++ ++
6 Berlinsulin H normal© (human insulin, phenol, protamine, glycerol) + ++ ++
7 Insulin Novo semilente© (porcine insulin, methyl-4-hydroxybenzoate, natrium acetate) + ++ ++
8 Humalog© (insulin lispro, m-cresol, glycerol, NaH2PO4 × H2O, zinc oxide) + + +
9 Novorapid© (insulin aspart, glycerol, m-cresol, phenol, NaH2PO4 × H2O) + + +
10 Apidra© (insulin glulisine, m-cresol, trometamol, polysorbate 20) + + +
11 Test solution A (NaH2PO4 × H2O 2.1 mg, glycerol 85% 18.8 mg, phenol 0.6 mg, m-cresol 1.5 mg in 
aqua dest. ad 1.0 ml)
-- -
12 Test solution B (glycerol 85% 18.8 mg, phenol 0.6 mg, m-cresol 1.5 mg in aqua dest. ad 1.0 ml) - - -
13 Test solution C (phenol 0.6 mg, m-cresol 1.5 mg in aqua dest. ad 1.0 ml) + - -
14 Test solution D (phenol 0.6 mg in aqua dest. ad 1.0 ml) + - -
15 Test solution E (m-cresol 1.5 mg in aqua dest. ad 1.0 ml) + - -
16 Test solution F (protamine 0.1 mg, NaH2PO4 × H2O 2.1 mg, glycerol 85% 18.8 mg, phenol 0.6 mg, 
m-cresol 1.5 mg in aqua dest. ad 1.0 ml)
++ + + +
17 Test solution G (protamine 0.1 mg in aqua dest. ad 1.0 ml) - ++ ++
18 Test solution H (zinc chloride 0.06 mg, glycerol 85% 20 mg, m-cresol 2.7 mg in aqua dest. ad 1.0 ml) - - -
19 Test solution I (glycerol 85% 20 mg, m-cresol 2.7 mg in aqua dest. ad 1.0 ml) - - -
20 Test solution J (m-cresol 2.7 mg in aqua dest. ad 1.0 ml) - - -
21 Aqua dest. -- -
22 NaCl 0.9% -- -
23 Histamine 0.01% +- -
Test solutions A-J were obtained from the Sanofi Aventis Insuman© test kit. Test results were noted 20 minutes, 24 hours, and 48 hours after 
injection. Interpretation of test results: -, no skin reaction; +, erythema and infiltrate with a diameter of <20 mm; ++, erythema and infiltrate with a 
diameter of >20 mm.Journal of Medical Case Reports 2008, 2:283 http://www.jmedicalcasereports.com/content/2/1/283
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Patch testing of the same substances and of different local
disinfectants was negative.
Laboratory testing
Analysis of a blood sample showed normal islet cell anti-
bodies (<1:10), elevated IgG antibodies against human
insulin (56 U/ml; normal value, <1 U/ml), and elevated
IgG antibodies against porcine insulin (12.4 ratio; normal
value, <10.0). IgE antibodies against human and porcine
insulin and against protamine were negative.
Histology
A skin biopsy taken from a plaque on an injection site of
the abdominal wall showed an Arthus-type reaction (Fig.
3).
Therapy
On day 1, we treated the patient with subcutaneous injec-
tions of human insulin (0.004, 0.01, 0.02, 0.04, 0.1, 0.2,
0.5, and 1.0 IU) using injection intervals of 30 minutes
with a daily allowance of 1.874 IU. Fexofenadin (180 mg
twice daily) was used as a concomitant medication as rec-
ommended by Grammer and coworkers [15]. On day 2,
we injected 1.0, 2.0, 3.0, and 5 IU using injection intervals
of 30 minutes. A daily allowance of 11 IU human insulin
was reached. On day 3, we switched to the formerly
incompatible insulin, Lantus©, given twice daily at a dose
of 6 IU. Therapy was well-tolerated on all days with nor-
moglycaemic values. On day 3, the local reactions
decreased to slight cutaneous reactions of 2 mm in diam-
eter. Up to the present time, the patient has tolerated this
form of therapy and fexofenadin treatment was reduced to
180 mg daily, and then stopped completely, 6 months
after desensitization.
Discussion
Successful treatment of allergies due to insulin prepara-
tions has been reported during the last few years. In cases
of hypersensitivity against protamine, the replacement of
protamine-containing insulins by insulins without this
Intradermal testing showing positive reactions against Lev- emir© (1), Huminsulin basal© (2), Humalog© (3), and Lantus© (4)  20 minutes after injection Figure 1
Intradermal testing showing positive reactions 
against Levemir© (1), Huminsulin basal© (2), Humalog© 
(3), and Lantus© (4) 20 minutes after injection. Hista-
mine (H) served as a positive, aqua dest. (Ø) as a negative 
control.
Results of intradermal testing using the Sanofi Aventis  Insuman© test kit Figure 2
Results of intradermal testing using the Sanofi 
Aventis Insuman© test kit. Protamine-containing test 
solutions (6 and 7) showed clear positive results 20 minutes 
after injections, while other components were negative.Journal of Medical Case Reports 2008, 2:283 http://www.jmedicalcasereports.com/content/2/1/283
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additive is the simplest strategy to solve the problem. In
patients in whom the insulin molecule itself causes local
or systemic allergies, the management of these complica-
tions becomes much more difficult. Many authors have
reported effective treatment using the insulin analogues,
aspart and lispro, instead of human regular insulin
[11,12,16]. Unfortunately, in our patient, intracutaneous
testing of insulin lispro, insulin aspart, and insulin gluli-
sine also caused an allergic test reaction. Therefore, a
change to one of the less immunogenic insulins did not
seem to be a promising option. Other groups have man-
aged insulin allergies with continuous subcutaneous insu-
lin infusions or with intravenously injected insulins
[8,9,17]. In all cases, these forms of therapy were success-
ful, but were in part associated with a restricted quality-of-
life. In severe cases, a solitary pancreas transplantation
was the last chance to treat a life-threatening insulin
allergy [13,14].
According to cases reported by Wessbecher et al. [18] in
2001 and Barranco et al. [19] in 2003, we devised an ultra-
rush treatment scheme using the subcutaneous adminis-
tration of human insulin. After 3 days of therapy, our
patient tolerated the formerly incompatible glargine insu-
lin and showed only minimal local reactions at the injec-
tion site and which did not exceed a diameter of 2 mm.
The mechanism of tolerance induction in general and in
our patient in particular still remains unclear. The most
common type of insulin allergy is related to an IgE-medi-
ated type I allergic reaction of the Coombs and Gell clas-
sification [2]. Less frequently, type III Arthus-type
reactions have been reported [2]. In addition, insulin
hypersensitivity can be related to a T-cell mediated type IV
reaction. Our patient exhibited two different forms of
hypersensitivity: 1) hypersensitivity against protamine
and 2) hypersensitivity against the insulin molecule itself.
As epicutaneous testing was completely negative, a T-cell
mediated form of allergy seemed to be improbable. Histo-
logic evaluation of a skin biopsy obtained from a local
reaction proved an Arthus-type reaction, clearly indicating
a type III reaction. Nevertheless, desensitization, such as
performed in our patient and usually only successful in
IgE-mediated type I reactions, was able to induce toler-
ance against formerly incompatible insulins.
Histologic slide of a skin biopsy obtained from an allergic skin reaction on the injection site: regular epidermis; congestion of  different inflammatory cells in blood vessels with emission in the adjacent connective tissue of deeper dermal parts Figure 3
Histologic slide of a skin biopsy obtained from an allergic skin reaction on the injection site: regular epidermis; 
congestion of different inflammatory cells in blood vessels with emission in the adjacent connective tissue of 
deeper dermal parts. Hematoxylin/eosin staining, magnification ×200; inset: Giemsa staining, magnification ×200.Publish with BioMed Central    and   every 
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Conclusion
We would like to recommend insulin desensitization
using an ultra-rush protocol with subcutaneous insulin
applications as a rapid and easy method of treatment,
even in cases in which intracutaneous testing is positive
for several or all insulin preparations on-hand.
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